Our research pipeline is designed to develop treatments for genetically defined subpopulations of patients suffering from dry AMD and linked diseases. This could provide patients with access to targeted first-in-class medicines for patients with limited therapeutic options.
Pipeline
Precision Medicine Pipeline
Age-Related Macular Degeneration
Target
Indication/Modality
Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3
GEM103 – Dry AMD, Geographic Atrophy
Recombinant CFH Protein
Systemic Renal
Target
Indication/Modality
Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3
GEM307
Potentiating Antibody